Michael C. Nivens

2.1k total citations · 1 hit paper
24 papers, 914 citations indexed

About

Michael C. Nivens is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Michael C. Nivens has authored 24 papers receiving a total of 914 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Physiology and 5 papers in Molecular Biology. Recurrent topics in Michael C. Nivens's work include Asthma and respiratory diseases (8 papers), Allergic Rhinitis and Sensitization (4 papers) and Urticaria and Related Conditions (3 papers). Michael C. Nivens is often cited by papers focused on Asthma and respiratory diseases (8 papers), Allergic Rhinitis and Sensitization (4 papers) and Urticaria and Related Conditions (3 papers). Michael C. Nivens collaborates with scholars based in United States, Germany and France. Michael C. Nivens's co-authors include George D. Yancopoulos, Hélène Goulaouic, Raolat M. Abdulai, Marcella Ruddy, Michael E. Wechsler, Klaus F. Rabe, Nikhil Amin, Kay Tetzlaff, Linda B. Ford and Andreas Jessel and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Biochemistry.

In The Last Decade

Michael C. Nivens

24 papers receiving 889 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

2021 258 citations Michael E. Wechsler, Marcella Ruddy et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Michael C. Nivens

Since Specialization

Citations

This map shows the geographic impact of Michael C. Nivens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael C. Nivens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael C. Nivens more than expected).

Fields of papers citing papers by Michael C. Nivens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael C. Nivens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael C. Nivens. The network helps show where Michael C. Nivens may publish in the future.

Co-authorship network of co-authors of Michael C. Nivens

This figure shows the co-authorship network connecting the top 25 collaborators of Michael C. Nivens. A scholar is included among the top collaborators of Michael C. Nivens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael C. Nivens. Michael C. Nivens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sarilumab in relapsing polymyalgia rheumatica: patient-reported outcomes from a phase 3, double-blind, randomised controlled trial 2025 ·The Lancet Rheumatology ·Vibeke Strand, Jérôme Msihid, (unknown), Michael C. Nivens, Jingdong Chao, Angeliki Giannelou, Stefano Fiore, (unknown), Bhaskar Dasgupta	4
2	Pharmacokinetics of Subcutaneous Itepekimab Injection With an Autoinjector Device and Prefilled Syringe in Healthy Participants 2024 ·Clinical Pharmacology in Drug Development ·Christine Xu, (unknown), Matthew P. Kosloski, Allison Butler, Hélène Goulaouic, Michael C. Nivens, (unknown)	1
3	Sa1275 IMPROVEMENTS IN HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS ARE MAINTAINED, OR CONTINUE TO IMPROVE, WITH LONG-TERM DUPILUMAB TREATMENT, REGARDLESS OF PRIOR ESOPHAGEAL DILATION 2024 ·Gastroenterology ·Albert J. Bredenoord, Evan S. Dellon, Ikuo Hirano, Changming Xia, Elizabeth Laws, Michael C. Nivens, Raolat M. Abdulai, Jennifer Maloney, Lila Glotfelty, Arsalan Shabbir	1
4	AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD 2024 ·ERJ Open Research ·Klaus F. Rabe, Fernando J. Martínez, Surya Prakash Bhatt, Tomotaka Kawayama, Borja G. Cosío, Robert Mróz, Maarten M. Boomsma, Hélène Goulaouic, Michael C. Nivens, Michel Djandji, Xavier Soler, (unknown), Matthew P. Kosloski, Christine Xu, Nikhil Amin, Heribert Staudinger, David J. Lederer, Raolat M. Abdulai	14
5	Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2) 2024 ·JAAD International ·Gil Yosipovitch, Brian Kim, Shawn G. Kwatra, Nicholas Mollanazar, Sonja Ständer, (unknown), Pedro Mendes‐Bastos, Tsen‐Fang Tsai, Elizabeth Laws, Michael C. Nivens, Jennifer Maloney, (unknown), Ashish Bansal, Ariane Dubost-Brama	5
6	Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials 2024 ·Clinical and Translational Science ·Matthew P. Kosloski, Emma Guttman‐Yassky, Michael J. Cork, Margitta Worm, Dong‐Ho Nahm, Xiaoping Zhu, Marcella Ruddy, Sivan Harel, Mohamed Kamal, Hélène Goulaouic, Christine Xu, (unknown), John D. Davis, Michael C. Nivens, Arsalan Shabbir, Allen Radin	8
7	A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis 2023 ·Arthritis Research & Therapy ·Wolfgang Schmidt, Bhaskar Dasgupta, (unknown), Angeliki Giannelou, Yuqing Xu, Sebastian Unizony, Sarah Mackie, Miguel Á. González‐Gay, Robert Spiera, Kenneth J. Warrington, Peter M. Villiger, Michael C. Nivens, Bolanle Akinlade, Yong Lin, Frank Buttgereit, John H. Stone	16
8	Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper 2023 ·New England Journal of Medicine ·Robert Spiera, Sebastian Unizony, Kenneth J. Warrington, (unknown), Angeliki Giannelou, Michael C. Nivens, Bolanle Akinlade, Wanling Wong, Rafia Bhore, Yong Lin, Frank Buttgereit, Valérie Devauchelle‐Pensec, Andrea Rubbert‐Roth, George D. Yancopoulos, Frédéric Marrache, Naimish Patel, Bhaskar Dasgupta	49
9	UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab 2022 ·The Pharmacogenomics Journal ·Nan Lin, Amy Damask, Anita Boyapati, Jennifer D. Hamilton, Sara Hamon, Nils Ternès, Michael C. Nivens, John S. Penn, Alexander Lopez, Jeffrey G. Reid, John D. Overton, Alan R. Shuldiner, Gonçalo R. Abecasis, Aris Baras, Charles Paulding	2
10	Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma breakdown → 2021 ·New England Journal of Medicine ·Michael E. Wechsler, Marcella Ruddy, Ian Pavord, Elliot Israel, Klaus F. Rabe, Linda B. Ford, Jorge Máspero, Raolat M. Abdulai, Chih-Chi Hu, Renata Martincova, Andreas Jessel, Michael C. Nivens, Nikhil Amin, David M. Weinreich, George D. Yancopoulos, Hélène Goulaouic	258
11	Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial 2021 ·The Lancet Respiratory Medicine ·Klaus F. Rabe, Bartolomé R. Celli, Michael E. Wechsler, Raolat M. Abdulai, Xiaodong Luo, Maarten M. Boomsma, Heribert Staudinger, Julie Horowitz, Aris Baras, Manuel A. R. Ferreira, Marcella Ruddy, Michael C. Nivens, Nikhil Amin, David M. Weinreich, George D. Yancopoulos, Hélène Goulaouic	119
12	Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis 2020 ·CPT Pharmacometrics & Systems Pharmacology ·Pavel Kovalenko, Anne Paccaly, Anita Boyapati, Christine Xu, Gregory St John, Michael C. Nivens, John D. Davis, (unknown), A. Thomas DiCioccio	9
13	Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment 2015 ·Pulmonary Pharmacology & Therapeutics ·Ian P. Hall, Andrew Fowler, Abhya Gupta, Kay Tetzlaff, Michael C. Nivens, Maria Sarno, Helen Finnigan, Eric D. Bateman, E. Rand Sutherland	68
14	The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies 2014 ·SpringerPlus ·Gregory Feldman, Jonathan A. Bernstein, Alan Hamilton, Michael C. Nivens, Lawrence Korducki, Craig LaForce	34
15	Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? 2011 ·Respiratory Medicine ·Lucas Goossens, Michael C. Nivens, (unknown), Brigitta U. Monz, Maureen Rutten‐van Mölken	23
16	In vivo inhibition of epidermal growth factor receptor autophosphorylation prevents receptor internalization 2010 ·Experimental Cell Research ·Michael W. Wolff, Kay Tetzlaff, Michael C. Nivens, (unknown), Birgit Jung, Jens M. Hohlfeld, Ralf Heilker	2
17	Safety and Efficacy of an Inhaled Epidermal Growth Factor Receptor Inhibitor (BIBW 2948 BS) in Chronic Obstructive Pulmonary Disease 2009 ·American Journal of Respiratory and Critical Care Medicine ·Prescott G. Woodruff, Michael W. Wolff, Jens M. Hohlfeld, Norbert Krug, Mark T. Dransfield, E. Rand Sutherland, Gerard J. Criner, Victor Kim, Antje Prasse, Michael C. Nivens, Kay Tetzlaff, Ralf Heilker, John V. Fahy	63
18	Responsiveness of the cough and sputum assessment questionnaire in exacerbations of COPD and chronic bronchitis 2009 ·Respiratory Medicine ·Brigitta U. Monz, (unknown), Jeffrey G. McDonald, Bruce Crawford, Michael C. Nivens, Kay Tetzlaff	25
19	The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase 2005 ·Cancer Research ·Adam I. Marcus, Jun Zhou, Aurora O’Brate, Ernest Hamel, Jason Wong, Michael C. Nivens, Adel K. El‐Naggar, Tso-Pang Yao, Fadlo R. Khuri, Paraskevi Giannakakou	93
20	Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase 2004 ·Cancer Chemotherapy and Pharmacology ·Michael C. Nivens, (unknown), (unknown), Maria Marjorette O. Peña, H. Trent Spencer, (unknown)	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact